Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Launching product...

    Launching product without Approval: DOP rejects Biocon Plea against NPPA action

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-02-24T11:25:05+05:30  |  Updated On 17 Aug 2021 12:25 PM IST

    New Delhi: Through a recent decision, the Department of Pharmaceuticals rejected the review applications filed by biopharmaceutical major Biocon against the decision of the National Pharmaceutical Pricing Authority (NPPA).


    Biocon, in its application, had challenged NPPA's retail price fixation of Blistro Trio 1 (containing Metformin Hcl (SR/ER/PR) 500+Voglibose 0.2mg+Glimepride 1mg tablet) and Blistro Trio 2 (containing Metformin Hcl (SR/ER/PR) 500+Voglibose 0.2mg+Glimepride 2mg tablet). NPPA had fixed the prices in 2017


    Biocon in its application contended that Blistro Trio 1 and 2 are being manufactured by Hetero Labs Ltd. and Biocon is only marketing the said products. Further, Hetero Lab has already taken the retail price approval from NPPA.


    "NPPA's stand of inclusion of M/s Biocon Ltd., fixing the retail prices of the said products, on the ground that the applicant company launched a new drug without obtaining a prior price approval is incorrect and erroneous," stated the plea


    However, NPPA stood for the inclusion of Biocon fixing the retail prices of the said products which is not agreed to by the company.


    It is reported that the company has also filed a plea with the Delhi High Court in order to seek quashing of the demand notice and price fixation orders by the NPPA for the mentioned drugs. The court directed the matter to the DOP to be heard and disposed off in a judicious and expedite the matter.

    Before the DOP, the company held that one of the ingredients of the said formulation namely Metformin Hcl (SR/ER/PR) 500+Voglibose 0.2mg+Glimepride 1mg and Metformin Hcl(SR/ER/PR) 500+Voglibose Page 2 of 4 0.2mg+Glimepride 2mg tablet on the date of launch of the formulations, were part of the NLEM 2011. Metformin Hcl(SR/ER/PR) 500 is different from Metformin Hcl 500. Thus, the said formulations could not be stated to be new drug in terms of DPCO.


    Furthermore, the company contended that NPPA did not observe the procedure laid down in paragraph 9(4) of DPCO. The paragraph states that the market data for fixing the retail price of the new drug for the month ending immediately before six months of receipt of an application for fixing the prices of new drug is to be taken into consideration.


    Thus, the data for the month of November, 2016 should have been taken into consideration by NPPA, as the application was filed by the company in May, 2017.


    Bengaluru-based Biocon also contended that since the company is not the existing manufacturer of the formulation and is only marketing the product being manufactured by Hetero Labs, at a price less than what was notified for Hetero Labs, the overcharged amount including interest and penalty levied by NPPA will not be applicable to them.


    Commenting on the challenges thrown, NPPA stated that Biocon did not take price approval before launching of Blistro Trio 1 tablet containing Metformin Hcl(SR/ER/PR) 500+Voglibose 0.2mg+Glimepride 1mg. and Blistro Trio 2 tablet containing Metformin Hcl(SR/ER/PR) 500+Voglibose 0.2mg+Glimepride 2mg. Moreover, NPPA's said approval is applicable for Hetero Lab Limited Ipca Lab Limited only for their product Glyree MV1 and Glyree MV2.


    "In regard to the contention of Biocon that under NLEM 2011 only Metformin tablet 500 mg is mentioned but their products contain Metformin Hcl 500mg (SR/ER/PR) and hence their products do not fall under the definition of new drug," states NPPA.


    NPPA stated that since under NLEM 2011, Metformin 500mg was included without differentiating its other variants, therefore, all variants, i.e. CR/SR/ER are considered as included. Hence, the contention of the applicant that Metformin 500mg tablet CR/SR/ER is not included in NLEM is not tenable.


    The regulatory body complied that since Biocon launched the product without taking prior price approval, NPPA issued show cause and demand notices as a followup action.


    Examining the entire issue, DoP has rejected Biocon's review order stating that the application is devoid of merit.


    The order was issued on the 22nd day of February 2019.


    Also Read: DOP rejects Review Petition of Lupin against ceiling price fixation for its combinations

    BioconBlistro trioBlistro trio 1blistro trio 2Department of PharmaceuticalDOPDPCODrugs Price Control OrderGlimeprideHeteroHetero labHetero LabsKiran ShawMetforminNational Pharmaceutical Pricing AuthorityNPPAreview orderreview petitionVoglibose

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok